Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-833-9 | CAS number: 872-93-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
Reproduction toxicity (OECD TG 422): NOAEL > 50 mg/kg bw/day (highest dose tested)
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- Combined 28-Day Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 05 Feb 2018 - 31 Aug 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- July 2016
- Deviations:
- yes
- Remarks:
- but none influenced validity of the study
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Crl: WI(Han)
- Details on species / strain selection:
- Outbred, SPF-Quality. The Wistar Han rat was chosen as the animal model for this study as it is an accepted rodent species for toxicity testing by regulatory agencies.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories
- Females: nulliparous and non-pregnant
- Age at study initiation (initiation of dosing): Males: approximately 10-12 weeks. Females: approximately 12-14 weeks.
- Weight at study initiation: Males: 250 to 350 g. Females: 200 to 250 g.
- Fasting period before study: no, except during motor activity measurements, animals will not have access to food for a maximum of 2 hours.
- Housing:
Pretest/pre-mating period (females only), recovery animals: group housed (5 animals, same sex and dosing) in polycarbonate cages
Mating phase, cohabitate Main males and Main females 1:1 in Macrolon plastic cages
Post-mating phase: Main males 5 males/cage, Females individual, Macrolon plastic cages.
Lactation: Main females Macrolon plastic cages, together with pups
The cages will contain appropriate bedding and will be equipped with water bottles.
During locomotor activity monitoring: F0-animals housed individually in a Hi-temp polycarbonate cage without cage enrichment,bedding material, food and water.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: at least 5 days prior to start of the pretest period (females) or at least 5 days before the commencement of dosing (males).
DETAILS OF FOOD AND WATER QUALITY: Pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany) will be provided ad libitum throughout the study, except during designated procedures. During motor activity measurements, animals will not have access to food for a maximum of 2 hours. The feed is analyzed by the supplier for nutritional components and environmental contaminants.
Municipal tap water is used Periodic analysis of the water is performed, and results of these analyses are on file at the Test Facility.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 18-24
- Humidity (%): 40-70
- Air changes (per hr): At least 10
- Photoperiod (hrs dark / hrs light): 12/12 (may be interrupted for designated procedures).
IN-LIFE DATES:
Arrival: males 28 Mar 2018 (Males), 14 Mar 2018 (Females)
Completion in life: 15 Jun 2018 - Route of administration:
- oral: gavage
- Details on exposure:
- Test item dosing formulations (w/w) are homogenized to visually acceptable levels at appropriate concentrations to meet dose level requirements. The dosing formulations are prepared daily and dosed within 6 hours after adding the vehicle to the test item. Test item dosing formulations were kept at room temperature until dosing. Adjustment is made for specific gravity of the test item. No correction was made for the purity/composition of the test item.
VEHICLE
- Amount of vehicle (if gavage): 5 mL/kg - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: max 14 days
- Proof of pregnancy: vaginal plug or sperm in vaginal smear, referred to as day 0 of pregnancy
- In case less than 9 females per group have shown evidence of mating, each non-mated female may be re-mated once with a male of proven fertility of the same group for a maximum of 7
days (if possible).
- Further matings after two unsuccessful attempts: no
- After successful mating each pregnant female was caged: individually - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples for Analysis: Duplicate middle samples for Groups 1 and 3 (concentration analysis only) and duplicate top, middle, and bottom samples for Groups 2 and 4 (concentration and homogeneity analysis).
Sample Volume: Approximately 500 mg accurately weighed.
Acceptance Criteria: For concentration, the criteria for acceptability were mean sample concentration results within or equal to ± 10% for solutions or ±15% for suspensions of target concentration. For homogeneity, the criteria for acceptability were a coefficient of variation (CV) of concentrations of ≤ 10% for each group. - Duration of treatment / exposure:
- Males were treated for a minimum of 28 days, up to and including the day before scheduled necropsy. This includes a minimum of two weeks prior to mating and during the mating period.
Females were treated for at least14 days prior to mating (with the objective of covering at least two complete estrous cycles), the variable time to conception, the duration of pregnancy and at least 14 days after delivery, up to and including the day before scheduled necropsy. Females were not dosed during littering. Animals were dosed approximately at the same time each day with a maximum of 6 hours difference between the earliest and latest dose. - Frequency of treatment:
- Daily
- Dose / conc.:
- 5 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 15 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 10 (additional 5 for 2 recovery groups)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on dose range finding study
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least once daily
BODY WEIGHT: Yes
- Time schedule for examinations: Males and females will be weighed on the first day of treatment (prior to dosing), and weekly thereafter.
FOOD CONSUMPTION: Weekly, except for Main males and Main females which are housed together for mating and for Main females without evidence of mating. Food consumption of mated Main females is measured on Days 0, 4, 7, 11, 14, 17, and 20 post-coitum and during lactation on PND 1, 4, 7 and 13.
WATER CONSUMPTION : Yes
- Time schedule for examinations: Regular basis throughout the study (visual examination)
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: One day after end of treatment on scheduled necropsy (main animals), on day of scheduled necropsy (recovery animals)
- Anaesthetic used for blood collection: Not specified
- Animals fasted: Yes (except F0 main females)
- How many animals: all main and recovery animals, two surplus pups per litter
- Parameters examined: White blood cells (WBC), Red Blood Cell Distribution Width (RDW), Neutrophils (absolute), Haemoglobin, Lymphocyte (absolute), Haematocrit, Monocytes (absolute), Mean corpuscular volume (MCV), Eosinophils (absolute), Mean corpuscular haemoglobin (MCH), Basophils (absolute), Mean corpuscular haemoglobin concentration (MCHC), Red blood cells platelets, Reticulocyte (absolute), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT).
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: One day after end of treatment on scheduled necropsy (main animals), on day of scheduled necropsy (recovery animals)
- Animals fasted: Yes (except F0 main females)
- How many animals: all main and recovery animals, two surplus pups per litter. T4 measurements only for F0 males.
- Parameters examined: Alanine aminotransferase (ALAT), Creatinine, Aspartate aminotransferase (ASAT), Glucose, Alkaline Phosphatase (ALP), Cholesterol, Total protein Sodium, Albumin Potassium, Total Bilirubin Chloride, Bile Acids, Calcium, Urea, Inorganic Phosphate (Inorg. Phos), Th
yroxine (T4).
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION / FUNCTIONAL TESTS: Yes
- Time schedule for examinations: males during week 4 of treatment, females during last week of lactation. Recovery animals at the end of the recovery phase.
- Dose groups that were examined: all (5 animals of each group)
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex, fore- and hind-limb grip strength, locomotor activity.
IMMUNOLOGY: No - Oestrous cyclicity (parental animals):
- Estrous cycle is evaluated by examining the vaginal cytology of samples obtained by vaginal lavage. Daily vaginal lavage was performed for all females (Main and Recovery) during 14 days prior to treatment (pretest period) and the first 14 days of treatment. For Main females, daily vaginal lavage continued during mating until evidence of copulation is observed. On the day of necropsy, a vaginal lavage was taken from all Main and Recovery females to determine the stage of estrus.
- Sperm parameters (parental animals):
- Parameters examined in Main male parental generations: testis weight, epididymis weight.
For males that fail to sire, a detailed qualitative examination is made, taking into account the tubular stages of the spermatogenic cycle. The examination is conducted in order to identify treatment related effects such as missing germ cell layers or types, retained spermatids, multinucleate or apoptotic germ cells and sloughing of spermatogenic cells into the lumen. - Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: yes
- If yes, maximum of 8 pups/litter (4/sex/litter as nearly as possible); excess pups were used for blood collection, killed and discarded.
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring: number and sex of pups, stillbirths, live births, postnatal mortality, clinical observations, weight gain, anogenital distance (AGD), presence of nipples/areolae in male pups, serum T4 levels.
GROSS EXAMINATION OF DEAD PUPS: Yes, for external and internal abnormalities; if possible. The cause of death was not determined for pups born or found dead. - Postmortem examinations (parental animals):
- SACRIFICE
- Main Males: after a minimum of 28 days of administration
- Main Females: PND 14-16
- Recovery Males: 14 days after end of treatment
- Recovery Females: at least 14 days after the first scheduled necropsy of Main females
GROSS PATHOLOGY: Yes
- Post mortem examination with special attention to reproductive organs. Number of former implantation sites, where no sites were macroscopically visible nongravid uteri were further examined using Salewski staining technique.
ORGAN WEIGHTS: Yes, for all selected main animals and all recovery animals
- Tissue examined: Brain, Cervix, Epididymis, Gland, adrenal, Gland, coagulation, Gland, parathyroid, Gland, prostate, Gland, seminal vesicle, Gland, thyroid, Heart, Kidney, Liver, Ovaries, Spleen, Testes, Thymus, Uterus.
- For all remaining main animals: Epididymis, Gland, coagulation, Gland, parathyroid, Gland, prostate, Gland, seminal vesicle, Gland, thyroid, Testes.
HISTOPATHOLOGY: Yes, with HE staining
- For selected main animals: Animal identification*, Artery, aorta*, Body cavity, nasopharynx*, Bone marrow, Bone, femur, Bone, sternum, Brain (seven levels), Cervix, Epididymis, Esophagus*, Eye, Gland, adrenal, Gland, coagulation, Gland, harderian*, Gland, lacrimal*, Gland,, mammary, Gland, parathyroid, Gland, pituitary, Gland, prostate, Gland, salivary*, Gland, seminal vesicle, Gland, thyroid, Gross lesions/masses, Gut-associated lymphoid tissued, Heart, Kidney, Large intestine, cecum, Large intestine, colon, Large intestine, rectum, Larynx*, Liver, Lung, Lymph node (mandibular and mesenteric site), Muscle, skeletal, Nerve, optica*, Nerve, sciatic, Ovaries, Pancreas*, Skin*, Small
intestine, duodenum, Small intestine, ileum, Small intestine, jejunum, Spinal cord, Spleen, Stomach, Testes, Thymus, Tongue*, Trachea, Urinary bladder, Uterus, Vagina.
*Collected but not processed for staining
- For males that failed to sire and female that failed to deliver pups: Cervix, epididymis, coagulation gland, prostate gland, seminal vesicles, ovaries, testes, uterus and vagina
- For remaining animals: Gross lesions/masses
- All remaining main animals (collected but not preserved): Animal identification, Cervix, Epididymis, Gland, coagulation, Gland, mammary, Gland, parathyroid, Gland, pituitary, Gland, prostate, Gland, seminal vesicle, Gland, thyroid, Gross lesions/masses, Ovaries, Testes, Uterus, Vagina. - Postmortem examinations (offspring):
- SACRIFICE
- On PND 4, the surplus pups (> 8 pups per litter) was euthanized by decapitation. From two surplus pups per litter, blood was collected, if possible. All remaining pups are euthanized on PND 14-16.
- These animals were subjected to postmortem examinations (macroscopic and/or microscopic examination) as follows: Sex is determined both externally and internally. Descriptions of all external abnormalities are recorded. Particular attention is paid to the external reproductive genitals to examine signs of altered development. External abnormalities are collected and fixed in 10% buffered formalin at discretion of the Study Director. In addition, the thyroid is collected from two pups per litter. - Statistics:
- All statistical tests were conducted at the 5% significance level. All pairwise comparisons were conducted using two sided tests and were reported at the 1% or 5% levels.
- Parametric: Datasets with at least 3 groups (the designated control group and 2 other groups) were compared using Dunnett-test (many-to-one-t-test).
- Non-parametric: Datasets with at least 3 groups was compared using a Steel-test (many-to-one rank test).
The motor activity data set was compared using an overall Kruskal-Wallis. The Wilcoxon Rank-Sum test was applied to compare the treated groups to the control group.
- Incidence: An overall Fisher’s exact test was used to compare all groups at the 5% significance level. The above pairwise comparisons were conducted using Fisher’s exact test whenever the overall test is significant. - Reproductive indices:
- Mating index (%), precoital time, number of implantation sites, fertility index (%).
- Offspring viability indices:
- Gestation index (%) and duration, Post-implantation survival index (%), Live birth index (%), Percentage live males at First Litter Check (%), Percentage live females at First Litter Check (%), Viability index (%), Lactation index (%).
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related clinical signs of toxicity were noted. Salivation was noted at 50 mg/kg in 9/15 females (lactating and nulliparous), starting after 5 weeks of treatment but was considered a physiological response.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Body weight gain of males at 50 mg/kg was slightly (statistically significant) lower than that of controls in the first week of the treatment period. As the change was only minor and complete recovery was seen in the subsequent period, it was not regarded as toxicologically relevant. A few statistically significant differences from controls were noted in females at the intermediate dose levels, but without a dose-related trend and therefore not considered related to treatment.
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- A statistically significant difference noted in females was regarded as unrelated to treatment due to its incidental occurrence.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Isolated, statistically significant intergroup differences observed at the end of the treatment period were regarded as unrelated to treatment due to the lack of a dose-related response.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Some statistically significant effects on ALAT, potassium, chloride, inorganic phosphate were noted for the high-dose groups, but all findings remained within histiorical control values. Statistically significantly higher (11%) creatinine values were observed in males and nulliparous females at the end of the recovery period, but were regarded as unrelated to treatment due to the lack of a test item-related change in creatinine at the end of the treatment period. Serum levels of T4 in F0-males were not affected by treatment.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Functional observation parameters were considered not to be affected by treatment and hearing ability, pupillary reflex and static righting reflex were normal in all examined animals. Minor statistically significant effects were noted for high-dose females with regard to grip strength and males with regard to motor activity. However, as these findings were within the historical control range, these effects were not considered treatment related. No other statistically significant differences were found.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
- Reproductive function: oestrous cycle:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Extended di-estrus during pairing was noted in three females (2 control group, 1 high-dose) with normal litters. The extended di-estrus for one animal could be explained by the continuation of vaginal lavages after mating (mating was overlooked in the initial assessment of the vaginal lavages). The extended di-estrus at 50 mg/kg was not attributed to treatment due to its incidental occurrence.
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, non-treatment-related
- Description (incidence and severity):
- An unusually high number of implantation sites (i.e. 19) was noted in one female of the high dose group. This finding was regarded as unrelated to treatment due to its incidental occurrence. The non-pregnancy of one mated female of the lowest dose group, without related histopathology changes in reproductive organs, was regarded as unrelated to treatment due to the incidental occurrence and lack of a dose-related trend.
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- > 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed (highest dose tested)
- Key result
- Critical effects observed:
- no
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The clinical signs observed incidentally remained within the range considered normal for pups of this age, and were therefore considered to be unrelated to treatment.
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- It was noted that mean body weights of male and female pups at 50 mg/kg were about 10% lower than those of control pups at PND 1 and 4. Except for the combined weight of male and female pups at PND 1, statistical significance was not achieved. Moreover, the relative differences from controls became smaller after culling and mean body weights of 50 mg/kg pups were close to the historical control group means. Therefore, pup body weight was considered not to be affected by treatment with the test item.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Serum T4 levels in male and female PND 14-16 pups were not affected by treatment.
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Other effects:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - No effect on areola/nipple retention in male pups
- The statistically significantly higher mean normalized anogenital distance noted in male pups at 15 mg/kg was regarded as unrelated to treatment due to the lack of a dose-related trend. - Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- > 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects observed (highest dose tested)
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Under the conditions of this study, no reproductive or developmental toxicity effects were observed and the NOAEL for both endpoints was established to be >50 mg/kg bw/day (highest dose tested). Therefore, the substance does not need to be classified for reproduction/developmental toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
- Executive summary:
The reproduction and developmental toxicity of 3-methyl sulfolane was evaluated in a Combined 28-Day Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in accordance with the OECD TG 422
and under GLP conditions. Dose levels were based on a dose-range finding study and set at 5, 15 and 50 mg/kg bw/day. Doses were analytically verified during the study. Two recovery groups were included to study persistence of possible effects in the dose groups. Effects on clinical signs, mortality, body weight (changes), food consumption, functional performance, hematology, clinical chemistry (including T4 analysis), gross necropsy, organ weights, histopathology and some reproductive parameters were
studied for the P1 generation. For the F1 generation mortality, clinical signs, body weights, macroscopic changes, anogenital distance, areola/nipple retention and total T4 levels.
The study was fully performed in accordance with the guideline and GLP conditions without any deviations that influence the validity. No significant adverse effects that were considered treatment-related were noted up to the highest dose tested in males and females (including recovery groups). This includes reproductive parameters and indices. Also no treatment-related effects were noted in the offspring, including limited developmental parameters. Based on these results, the NOAEL for both endpoints (reproduction and developmental) was established to be >50 mg/kg bw/day (highest dose tested). Therefore, the substance does not need to be classified for reproduction/developmental toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Under the conditions of this study, no reproductive or developmental toxicity effects were observed and the NOAEL for both endpoints was established to be >50 mg/kg bw/day (highest dose tested). Therefore, the substance does not need to be classified for reproduction/developmental toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
Additional information
The reproduction and developmental toxicity of 3-methyl sulfolane was evaluated in a Combined 28-Day Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in accordance with the OECD TG 422
and under GLP conditions. Dose levels were based on a dose-range finding study and set at 5, 15 and 50 mg/kg bw/day. Doses were analytically verified during the study. Two recovery groups were included to study persistence of possible effects in the dose groups. Effects on clinical signs, mortality, body weight (changes), food consumption, functional performance, hematology, clinical chemistry (including T4 analysis), gross necropsy, organ weights, histopathology and some reproductive parameters were studied for the P1 generation. For the F1 generation mortality, clinical signs, body weights, macroscopic changes, anogenital distance, areola/nipple retention and total T4 levels.
The study was fully performed in accordance with the guideline and GLP conditions without any deviations that influence the validity. No significant adverse effects that were considered treatment-related were noted up to the highest dose tested in males and females (including recovery groups). This includes reproductive parameters and indices. Also no treatment-related effects were noted in the offspring, including limited developmental parameters. Based on these results, the NOAEL for both endpoints (reproduction and developmental) was established to be >50 mg/kg bw/day (highest dose tested). Therefore, the substance does not need to be classified for reproduction/developmental toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Justification for classification or non-classification
Based on the available data, the substance does not need to be classified for reproduction toxicity in accordance with the criteria outlined in Annex I of the CLP Regulation (1272/2008/EC).
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.